Next Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$255K Hold
2,000
0.08% 111
2025
Q4
$244K Hold
2,000
0.08% 114
2025
Q3
$200K Buy
+2,000
New +$180K 0.07% 125
2023
Q2
Sell
-2,000
Closed -$152K 129
2023
Q1
$152K Buy
+2,000
New +$166K 0.07% 117
2019
Q4
Sell
-1,000
Closed -$76K 225
2019
Q3
$76K Sell
1,000
-1,500
-60% -$125K 0.05% 121
2019
Q2
$219K Hold
2,500
0.15% 80
2019
Q1
$226K Hold
2,500
0.19% 76
2018
Q4
$179K Buy
+2,500
New +$201K 0.16% 78

Other funds holding XBI

Next Capital Management's XBI Position: Q1 2026 in Review

Next Capital Management held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q1 2026 at 2,000 shares worth $255K. The position accounts for 0.08% of the portfolio, ranked #111.

Next Capital Management first reported a position in XBI in Q4 2018 and has held it in 8 quarters since. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Next Capital Management held 2,000 shares of State Street SPDR S&P Biotech ETF worth $255K as of Q1 2026.
  • Next Capital Management left its State Street SPDR S&P Biotech ETF share count unchanged in Q1 2026.
  • State Street SPDR S&P Biotech ETF made up 0.08% of Next Capital Management's portfolio in Q1 2026, its #111 holding.
  • Next Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2018 and has held it in 8 quarters since.
  • 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Next Capital Management's 13F filing for Q1 2026, filed 7 May 2026.